Related Experiment Video
Updated: Jan 21, 2026

Author Spotlight: Studying Behavior of Acanthamoeba to Develop Targeted Strategies for Preventing Acanthamoeba Keratitis
Published on: September 20, 2024
In Vitro Evaluation of Combined Commercialized Ophthalmic Solutions Against Acanthamoeba Strains
María Reyes-Batlle1, Glorian Mura-Escorche1, Ines Sifaoui1
1Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna. Av. Astrofísico Francisco Sánchez S/N, 38203 Tenerife, Spain.
Abstract:
Acanthamoeba is a free-living amoebae genus which is present worldwide in natural and artificial environments. These amoebae are clinically important as causative agents of diseases in humans and other animals such as a fatal encephalitis or a sight threatening Acanthamoeba keratitis (AK). Lately; studies have focused on the search of novel therapeutic options for AK but also to prevent infections. Furthermore; the evaluation of commercialized products seems to be an option for this case since not clinical assays would be required. Thus; we aimed to test the amoebicidal activity of different mixtures of two commercial ophthalmic solutions: Systane® Ultra; which has already shown anti-Acanthamoeba properties; and Naviblef® Daily Care. In addition, we tested their cytotoxic effect against murine macrophages. At the individual level; Naviblef® Daily Care showed to be the most active product against Acanthamoeba spp. Nevertheless; the combinations of Systane® Ultra and Naviblef® Daily Care; showed an improvement in the activity against trophozoites and cysts of Acanthamoeba castellanii Neff. Moreover; the concentration necessary to generate cytotoxic effect against murine macrophages (J774.1) was much higher than the required for the amoebicidal and cysticidal effect achieved in the most effective mixtures.
Insights
Novel ophthalmic solution mixtures show promise for treating Acanthamoeba infections. Combining Systane® Ultra and Naviblef® Daily Care demonstrated potent amoebicidal and cysticidal effects with low cytotoxicity, offering a potential therapeutic strategy for Acanthamoeba keratitis.
Area of Science:
- Ophthalmology
- Microbiology
- Parasitology
Background:
- Acanthamoeba species are ubiquitous protozoa causing severe human diseases like Acanthamoeba keratitis (AK).
- Developing effective and safe treatments for AK is crucial due to its sight-threatening nature.
- Evaluating existing commercial products offers a faster route to potential AK therapies.
Purpose of the Study:
- To assess the amoebicidal and cysticidal activity of Systane® Ultra and Naviblef® Daily Care ophthalmic solutions.
- To investigate the efficacy of combinations of these two commercial products against Acanthamoeba.
- To evaluate the cytotoxic effects of these solutions on murine macrophages.
Main Methods:
- Testing the anti-Acanthamoeba activity of individual ophthalmic solutions.
- Evaluating synergistic effects of combined Systane® Ultra and Naviblef® Daily Care.
- Assessing cytotoxicity against J774.1 murine macrophage cell line.
Main Results:
- Naviblef® Daily Care exhibited significant activity against Acanthamoeba spp. individually.
- Combinations of Systane® Ultra and Naviblef® Daily Care enhanced amoebicidal and cysticidal effects against Acanthamoeba castellanii.
- Effective amoebicidal concentrations were substantially lower than cytotoxic concentrations for macrophages.
Conclusions:
- Mixtures of Systane® Ultra and Naviblef® Daily Care demonstrate potent anti-Acanthamoeba activity.
- These combinations present a promising therapeutic approach for Acanthamoeba infections, particularly AK.
- The tested ophthalmic solution mixtures show a favorable safety profile with low cytotoxicity.
Related Concept Videos
Ideal Solutions
General Properties of Solutions
Solution Formation
This selective...
Enthalpy of Solution
Thermal Strain
Shearing Strain

